Soluble epoxide hydrolase inhibition attenuates aortic plaque formation in a murine model of accelerated atherogenesis

Arzu Ulu,Benjamin B. Davis,Hsing‐Ju Tsai,In‐Hae Kim,Bruce D. Hammock,Robert H. Weiss
DOI: https://doi.org/10.1096/fasebj.22.1_supplement.479.47
2008-03-01
The FASEB Journal
Abstract:Epoxyeicosatrienoic acids (EETs) have hemodynamic and anti‐inflammatory effects. They can be stabilized in vivo by inhibiting the soluble epoxide hydrolase (sEH). Epoxide hydration appears to be the major route of metabolism. For this reason, sEH inhibitors (sEHIs) are being developed as potential pharmaceuticals for the treatment of cardiovascular and inflammatory diseases. To determine the effect of sEHIs on atherosclerotic lesion formation, we utilized an established mouse model of accelerated atherogenesis: 5 months old male Apo E (−/−) mice. ApoE(−/−) mice were treated with sEHI 1‐adamantyl‐3‐(5‐(2‐(2‐ethoxyethoxy) ethoxy) pentyl urea (AEPU) in drinking water (90μg/ml) for two months. During the last month of the study, all animals were fed an atherogenic diet and were simultaneously infused with angiotensin‐2 by osmotic minipumps to induce atherosclerosis. The descending aortas were examined for areas of plaque within their lumens. In animals that received the sEH inhibitor we observed a 53% reduction in atherosclerotic lesions as compared to control animals. A highly significant increase in plasma arachidonic and linoleic acid epoxides (EETs and EpOMEs) was observed in the AEPU treated group. Our data suggest that orally‐available sEHIs may be useful in the treatment of atherosclerosis by directly attenuating plaque formation.
cell biology,biochemistry & molecular biology,biology
What problem does this paper attempt to address?